Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.

Summary

MagPEP is a multi-centre, randomized, phase III, double blind, placebo controlled, parallel group trial. It evaluates magnesium sulfate for the prevention of post-ERCP pancreatitis. Adult patients with a medical indication for ERCP are to be randomized (1:1 ratio) to receive either magnesium sulfate or placebo (NaCl 0,9%) 60 min before and 6 hours after ERCP.

Timeline

Start

2012-08-27

Primary completion

2020-07

Completion

2020-08-31

Drugs

Indications